New data show Victoza® helped reduce blood sugar when patients with type 2 diabetes switched from sitagliptin or exenatide

Another study shows benefits of adding Levemir® insulin therapy to Victoza®San Diego, CA (June, 2011) Novo Nordisk will present data from two extension studies at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) which show that Victoza® (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped more patients achieve blood sugar control when compared with other commonly used type 2 diabetes therapies. Although not a weight loss product, the data also demonstrate that patients experienced significant weight